Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026)

Invivyd's (IVVD) quarterly Liabilities and Shareholders Equity came in at $218.9 million in Q2 2026, up 145.56% on a YoY basis from $89.1 million in Q2 2025, and down 20.95% quarter-over-quarter from $276.9 million in Q4 2025.

Analysis

Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $218.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 145.56% year-over-year to $218.9 million; the trailing twelve-month figure through Jun 2026 stood at $724.1 million (up 49.5% YoY), and the FY2025 full-year result was $276.9 million, up 113.78% from the prior year.
  • Liabilities and Shareholders Equity retreated to $218.9 million in Q2 2026 per IVVD's latest filing, from $276.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $556.3 million in Q1 2022 and bottomed at $89.1 million in Q2 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $266.5 million across 5 years, with a median of $229.2 million in 2023.
  • The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 51.85% in 2025, then soared 145.56% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $383.2 million in 2022, then slumped by 40.19% to $229.2 million in 2023, then tumbled by 43.49% to $129.5 million in 2024, then surged by 113.78% to $276.9 million in 2025, then decreased by 20.95% to $218.9 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $218.9 million, $276.9 million, and $139.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 10.03 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 5.56 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 32.09 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 2.10 Bn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn 218.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 218.88 Mn
Dec 31, 2025 276.88 Mn
Sep 30, 2025 139.16 Mn
Jun 30, 2025 89.14 Mn
Mar 31, 2025 103.74 Mn
Dec 31, 2024 129.52 Mn
Sep 30, 2024 161.92 Mn
Jun 30, 2024 177.35 Mn
Mar 31, 2024 215.47 Mn
Dec 31, 2023 229.18 Mn
Sep 30, 2023 274.92 Mn
Jun 30, 2023 315.41 Mn
Mar 31, 2023 350.56 Mn
Dec 31, 2022 383.17 Mn
Sep 30, 2022 424.75 Mn
Jun 30, 2022 484.61 Mn
Mar 31, 2022 556.27 Mn
Dec 31, 2021 620.09 Mn
Sep 30, 2021 686.27 Mn
Jun 30, 2021 397.99 Mn